default author photo

Etienne Brain

Institut Curie - Department of Medical Oncology

SCHOLARLY PAPERS

3

DOWNLOADS

171

TOTAL CITATIONS

3

Scholarly Papers (3)

1.

70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT

Number of pages: 22 Posted: 23 Oct 2020
Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of California, San Francisco (UCSF), European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Gustave Roussy Villejuif, Université Paris VI Pierre et Marie Curie - Institut Curie, Catholic University of Louvain (UCL) - CHU Site Sainte-Elisabeth, Institut Curie - Department of Medical Oncology, Noordwest Ziekenhuisgroep, Alrijne Ziekenhuis, Centre Georges-Francois Leclerc, Jeroen Bosch Ziekenhuis, European Institute of Oncology (IEO) IRCCS, Agendia, University of Lausanne - Swiss Institute of Bioinformatics (SIB), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of Navarra - Clínica Universidad de Navarra, Kliniken Essen-Mitte - Breast Unit, Università degli Studi di Genova - Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Baylor College of Medicine, Institute of Oncology, University of Lausanne - Lausanne University Hospital, Breast International Group Headquarters, Breast International Group Headquarters, University of Texas Health Science Center at San Antonio, Europa Donna-European Breast Cancer Coalition, Merck & Co., Inc., European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Champalimaud Foundation - Champalimaud Clinical Center and Netherlands Cancer Institute
Downloads 94 (720,278)
Citation 3

Abstract:

Loading...

breast cancer, genomics, adjuvant treatment, clinical trial

2.

Current and Evolutionary Analysis of Early Relapsed Metastatic Triple Negative Breast Cancer in the Nationwide ESME Cohort

Number of pages: 24 Posted: 12 Apr 2023
Gustave Roussy, University of Claude Bernard Lyon 1 - Department of Clinical Research Centre, University of Montpellier, École Normale Supérieure - PSL Research University - Institut Curie, Institut Curie - Department of Medical Oncology, Institut de Cancérologie de l’Ouest Pays de Loire, CHU Lille - Centre Oscar Lambret, Institut Claudius Regaud - IUCT-Oncopole, CRCT, Inserm, Aix-Marseille University, Centre Henri Becquerel, Centre Jean Perrin, Centre François Baclesse - Department of Medical Oncology, Centre François Baclesse, Institut de Cancérologie de Bourgogne, Institut de Cancérologie de Lorraine, Centre Paul Strauss, Institut Jean Godinot - Department of Medical Oncology, Bergonié Institute, R&D Unicancer, R&D Unicancer, University of Claude Bernard Lyon 1 - Medical Oncology Department, Institut Curie - Department of Medical Oncology, University of Claude Bernard Lyon 1 - Department of Clinical Research Centre, Gustave Roussy - Breast Cancer Unit and Gustave Roussy Villejuif
Downloads 54 (1,031,043)

Abstract:

Loading...

Key words: breast cancer, triple-negative breast cancer, real-world data, ESME cohort, overall survival, ESME cohort

3.

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

Number of pages: 25 Posted: 19 Apr 2026
University of Montpellier, UNICANCER, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Institut de Cancérologie de Lorraine, Institut de Cancérologie de l’Ouest Pays de Loire, University of Claude Bernard Lyon 1 - Department of Clinical Research Centre, Institut Curie - Department of Medical Oncology, CHU Lille - Centre Oscar Lambret, University of Claude Bernard Lyon 1 - Medical Oncology Department, Bergonié Institute, UNICANCER and Centre Eugene Marquis
Downloads 23 (1,448,301)

Abstract:

Loading...

metastatic breast cancer, Real-world evidence, HER2-low, HR-positive, trastuzumab deruxtecan